May 17, 2013
/PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO,
, will present the Company's corporate overview on
Monday, May 20, 2013
at the UBS Global Health Care Conference. The conference will be held at the Sheraton New York Hotel in
New York City
The Company's lead development program is Oxycodone DETERx
, an abuse-deterrent, extended-release oxycodone product utilizing its proprietary DETERx
technology. The Oxycodone DETERx
formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.
About DETERx® Technology
drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastrostomy tube, while maintaining the extended-release properties of the product. DETERx
technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx
is the first of a number of product candidates using the DETERx
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx
formulation platform for the treatment of chronic pain. The DETERx
oral drug delivery technology provides extended release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at
, PresidentCollegium Pharmaceutical, Inc.781-713-3722
SOURCE Collegium Pharmaceutical, Inc.